Citing a lack of long-term scientific evidence, anti-tobacco activists often refuse to endorse vaping as a safer alternative to smoking. In fact, many have gone so far as to falsely claim that vaping is just as carcinogenic and dangerous to one’s health as smoking. But a new vaping study funded by the Big Tobacco subsidiary Fontem Ventures and conducted by an independent team of third-party scientists makes definitively clear that vaping produces no adverse health effects, especially regarding the heart and lungs.
Overview of the 2-year vaping study
The researchers began by soliciting the help of over 200 volunteers to participate in the 2-year vaping study. Periodically, the scientists would call collect and analyze an extensive combination of biomarkers. The results are published in a report entitled Evaluation of the safety profile of an electronic vapour product used for two years by smokers in a real-life setting via the Science Direct website.
- An initial control group of 209 vapers participated in the research.
- Only 102 completed the full 2-year study.
- The others were either rejected or disqualified at some point during the study for failing to meet or maintain the study’s strict protocols for participation (i.e.: relapsing back into smoking, trying vaping only once, or withdrawing due to unforeseen health issues unrelated to vaping).
- All participants were given the same vaping device and tobacco-flavored e-liquid.
- After three months, a menthol alternative was also provided.
- Biomarkers were collected at Months 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24.
- Biomarkers measured include:
- Blood Pressure
- Heart Rate
- Body weight
- Nicotine exposure levels
- Exposure levels of toxicities and carcinogens commonly associated with combustible tobacco products
- Respiratory functions (monitored via spirometry technology)
- Blood carboxyhaemoglobin (COHb) levels
- Other vital signs and cardiovascular functions
The researchers not only discovered that vaping posed no adverse health risks regarding the heart and lungs after a full 2-years of regular vaping, they also determined that vaping helps reduce the withdrawals symptoms that often appear when smokers are trying to quit.
“To our knowledge, our study is the only one so far that monitored urinary BoE over 2 years of EVP use in a real-life setting, showing a sustained reduced exposure to HPHCs, with sustained nicotine levels close to baseline. Exposure to HPHCs had a tendency to increase from Month 23 to Month 24, which is consistent with the observed CC consumption towards EoS. This increase is likely to be a sign of compliance loosening when the end of the study approaches. In EVP-compliant subjects, exposure to HPHCs decreased from baseline to Month 1, and stayed slightly lower than in the whole population throughout the study, which is also consistent with CC consumption data in that group of subjects.”
The Fontem research follows closely on the heels of another longitudinal vaping study led by Italian scientist Riccardo Polosa of the University of Catania. The Polosa study lasted over 3.5 years and was released in mid-2017. Both studies indicate strikingly similar findings, specifically that vaping produces no adverse health effects of measurable significance over the long term. The Italian study entitled Health impact of E-cigarettes: a prospective 3.5-year study of regular daily users who have never smoked is readily available for review via the medical journal Nature.